Fauna Bio has achieved a significant milestone in its partnership with Eli Lilly by designating a metabolic disease drug target for obesity, identified through its innovative AI discovery platform. This development, rooted in biological insights from hibernating squirrels, triggers a milestone payment as part of a multi-year agreement potentially worth up to $494 million. Fauna’s CEO, Ashley Zehnder, emphasizes that studying the unique metabolic regulation of hibernating mammals can unveil therapeutic targets that traditional methods have overlooked.

This research is particularly relevant in the context of the competitive obesity treatment landscape, where existing GLP-1 weight loss drugs have shifted focus toward addressing underlying metabolic mechanisms. Fauna’s approach aims to tackle common challenges in obesity care, such as metabolic rate reduction post-weight loss, and explores strategies to preserve lean muscle mass during weight reduction therapies.

For professionals in the longevity and healthspan fields, this partnership exemplifies the potential of leveraging comparative genomics to uncover novel therapeutic pathways. I encourage you to read the full article to delve deeper into Fauna’s groundbreaking findings and their implications for future obesity treatments.

Source: longevity.technology